Emmaus Life Sciences announces patent allowance from European Patent Office
Emmaus Life Sciences announced the allowance of patent application number 12860587.0, directed to the treatment of diverticulosis, by the European Patent Office. The allowance of this application follows the issuance of corresponding patents in the United States, Japan, Australia, Mexico, China, Indonesia, South Korea and Russia. Patent applications are currently pending in various jurisdictions around the world, including Brazil and India. The allowed European application reports a significant reduction in the number of intestinal diverticula, the primary indicator of diverticulosis, through the therapeutic application of -pharmaceutical-grade L-glutamine, or PGLG. There are no commercial therapies that claim an ability to reduce intestinal diverticula at the present time. The covered invention is directed to methods and/or compositions for the treatment of diverticulosis. It is more specifically directed to compositions including PGLG or uses of such compositions in the treatment of diverticulosis. Diverticulosis refers to a condition where pouches form along the colon wall. Over time, some people get an infection in the pouches.